Feasibility of using long noncoding RNAs for predicting malignant transformation of cervical epithelium


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective: To investigate expression levels of long noncoding RNAs linc-ROR and MALAT1 in the normal cervical epithelium and cervical intraepithelial neoplasia and evaluate the change in their expression depending on the severity of cervical dysplasia. Materials and methods: The study included 89 reproductive age patients with histologically confirmed LSIL and HSIL and high-risk type of HPV. The comparison group included 40 patients with cytologically excluded cervical disease and test negative for HPV. The expression levels of long noncoding RNAs linc-ROR and MALAT1were analyzed by Real-Time PCR using primers specific for these genes. Results: The expression level of MALAT1 in cervical dysplasia was statistically significantly higher than in the control group, with 62.5% of patients having LSIL of 2.6±0.42 and 79.8% having HSIL of 4.9 ± 2.65 (p<0.001, Kruskal-Wallis test). No statistically significant differences between the groups were found in linc-ROR expression (LSIL 2.07±0.34, HSIL 1.91±0.86 in the study group, and 1.0±0.4 in the comparison group (p = 0.368) (Kruskal - Wallis test), which indicates no predictive value of linc-ROR for the diagnosis of precancerous lesions of the cervix. Conclusion: The search for early diagnostic markers of malignant transformation of the cervical epithelium is a priority research area aimed to reduce the incidence of cervical cancer. This study demonstrated an increase in the level of MALAT1 expression in LSIL in 62.5% and HSIL in 79.8% of patients compared with normal cervical epithelium, which indicates a high proliferative activity of cells, degradation of the gene p53 suppressing tumor growth, and blockage of apoptosis. Therefore, MALAT1 may become a promising biomarker for the progression of cervical dysplasia.

Full Text

Restricted Access

About the authors

Sergey A. Levakov

I.M. Sechenov First Moscow State Medical University Ministry of Health of Russia (Sechenov University)

Email: levakoff@yandex.ru
Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology, NV. Sklifosovsky ICM 119991, Russia, Moscow, Trubetskaya str., 8-2

Elizaveta A. Obukhova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: liza_obukhova@mail.ru
Teaching Assistant at the Department of Obstetrics and Gynecology, NV. Sklifosovsky ICM 119991, Russia, Moscow, Trubetskaya str., 8-2

Natalia A. Sheshukova

I.M. Sechenov First Moscow State Medical University Ministry of Health of Russia (Sechenov University)

Email: dr.sheshukova@mail.ru
Dr. Med. Sci., Professor at the Department of Obstetrics and Gynecology, NV. Sklifosovsky ICM 119991, Russia, Moscow, Trubetskaya str., 8-2

Olesya V. Bol'shakova

Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies of the Federal Medical Biological Agency

Ph.D., Associate Professor at the Department of Obstetrics and Gynecology of the Academy of Postgraduate Education 125371, Russia, Moscow, Volokolamsk highway, 91

Mikhail I. Shakhparonov

M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry RAS

Email: shakhparonov@gmail.com
Dr. Sci. (Chemistry), Head of the Laboratory of Membrane and Bioenergetic Systems, Institute of Bioorganic Chemistry 117997, Russia, Moscow, Miklukho-Maklaya str., 16/10

Nadezhda V. Antipova

M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry RAS; RUDN University

Email: nadine.antipova@gmail.com
Ph.D. (Bio), Senior Researcher at the Laboratory of Membrane and Bioenergetic Systems, Institute of Bioorganic Chemistry; Associate Professor at the Department of Pharmaceutical and Toxicological Chemistry 117997, Russia, Moscow, Miklukho-Maklaya str., 16/10

References

  1. Пак Р.В. Эпидемиологические особенности рака шейки матки в мире. Вестник КазНМУ. 2019; 1: 675-7.
  2. Шахтахтинская Ф.Ч., Намазова-Баранова Л.С., Таточенко В.К., Новикова Д.А., Ткаченко Н.Е. Вирус папилломы человека. Профилактика ВПЧ-ассоциированных заболеваний. Педиатрическая фармакология. 2015; 12(1): 74-8.
  3. Arbyn M., Gultekin M., Morice P., Nieminen P. et al. The European response to the WHO call to eliminate cervical cancer as a public health problem. Int J Cancer. 2021; 148: 277-84. https://doi.org/10.1002/ijc.33189.
  4. Ашрафян Л.А., Киселев В.И., Кузнецов И.Н., Серова О.Ф., Узденова З.Х., Герфанова Е.В. Рак шейки матки: проблемы профилактики и скрининга в Российской Федерации. Доктор.ру. 2019; 11(166): 50-4. https://doi.org/10.31550/1727-2378-2019-166-11-50-54.
  5. Bedell S.L., Goldstein L.S., Goldstein A.R., Goldstein A.T. Cervical Cancer Screening: Past, Present, and Future. Sex Med Rev. 2020; 8: 28-37. https://doi.org/10.1016/j.sxmr.2019.09.005.
  6. Рябая О.О., Прокофьева А.А. Взаимодействие аутофагии и эпителиальномезенхимального перехода в развитии опухолевой прогрессии. Успехи молекулярной онкологии. 2020; 7(2): 8-19. https://doi.org/10.17650/2313-805X-2020-7-2-8-19.
  7. Pan Y., Zhang K., Li C., Chen J. et al. The Emerging Roles of Long Noncoding RNA ROR (lincRNA-ROR) and its Possible Mechanisms in Human Cancers. Cellular Physiology and Biochemistry. 2016; 40(1-2): 219-29. https://doi.org/10.1159/000452539.
  8. Xu X.Y., Zhang J., Qi Y.-H., Kong M., Liu S.-A., Hu J.-J. Linc-ROR promotes endometrial cell proliferation by activating the PI3K-Akt pathway. Eur Rev Med Pharmacol Sci. 2018; 22(8): 2218-25. https://doi.org/10.26355/eurrev_201804_14807.
  9. Бейлерли О.А., Гареев И.Ф., Павлов В.Н., Shiguang Z., Xin C., Кудряшов B.В. Экзосомальные длинные некодирующие РНК как биомаркеры и терапевтические мишени при раке. Креативная хирургия и онкология. 2019; 9(4): 297-304. https://doi.org/10.24060/2076-3093-2019-9-4-297-304.
  10. Архангельская П.А., Бахидзе Е.В., Берлев И.В., Самсонов Р.Б., Иванов М.К., Малек А.В. Микро-РНК, ВПЧ-инфекция и цервикальный канцерогенез: молекулярные аспекты и перспективы клинического использования. Сибирский онкологический журнал. 2016; 15(4): 88-97. https://doi.org/10.21294/1814-4861-2016-15-4-88-97.
  11. Chen W., Yang J., Fang H., Li L., Sun J. Relevance Function of Linc-ROR in the Pathogenesis of Cancer. Front Cell Dev Biol. 2020; 8: 696. https://doi.org/10.3389/fcell.2020.00696.
  12. Yang L., Bai H.-S., Deng Y., Fan L. High MALAT1 expression predicts a poor prognosis of cervical cancer and promotes cancer cell growth and invasion. Eur Rev Med Pharmacol Sci. 2015; 19(17): 3187-93.
  13. Shen F., Zheng H., Zhou L., Li W., Xu X. Overexpression of MALAT1 contributes to cervical cancer progression by acting as a sponge of miR-429. J Cell Physiol. 2019; 234(7): 11219-26. https://doi.org/10.1002/jcp.27772.
  14. Бейлерли О.А., Гареев И.Ф. Роль длинных некодирующих РНК в биологии опухолей. Бюллетень сибирской медицины. 2020; 19(1): 125-33. https://doi.org:10.20538/1682-0363-2020-1-125-133.
  15. Li C., Lu L., Feng B., Zhang K., Han S., Hou D.-R., Chen L.-B., Chu X., Wang R. The lincRNA-ROR/miR-145 axis promotes invasion and metastasis in hepatocellular carcinoma via induction of epithelial-mesenchymal transition by targeting ZEB2. Scientific Reports. 2017; 7(1): 4637. https://doi.org/10.1038/s41598-017-04113-w.
  16. Zhou Q., Guo J., Huang W., Yu X., Xu C., Long X. Linc-ROR promotes the progression of breast cancer and decreases the sensitivity to rapamycin through miR-194-3p targeting MECP2. Mol Oncol. 2020; 14(9): 2231-50. https://doi.org/10.1002/1878-0261.12700.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies